Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant <i>Mycobacterium tuberculosis</i>

Sander P. van Rijn, Marlanka A. Zuur, Richard Anthony, Bob Wilffert, Richard van Altena, Onno W. Akkerman, Wiel C.M. de Lange, Tjip S. van der Werf, Jos G. W. Kosterink, Jan‐Willem C. Alffenaar

Antimicrobial Agents and Chemotherapy · 2018 · 38 citations · 57 references

DOIFull text

Open access

Concepts

Abstract

studies have been performed, including one prospective, two observational, and seven retrospective clinical studies to assess the effectiveness, safety, and tolerability of three different carbapenems (imipenem, meropenem, and ertapenem). We found no clear evidence at the present time to select one particular carbapenem among the different candidate compounds to design an effective M/XDR-TB regimen. Therefore, more clinical evidence and dose optimization substantiated by hollow-fiber infection studies are needed to support repurposing carbapenems for the treatment of M/XDR-TB.

References

57